Stay up-to-date with the biggest stories in tech and business. Every weekday.

Connected

Stay connected with the biggest global stories in business and tech. Presented by Karleen Leveille, every weekday on Curio.

In today's episode...

Elon Musk's brain-implant company Neuralink has FDA approval to conduct its first human trial. But can a device actually link our brains to computers? And is it safe? The Washington Post tells you everything you need to know. 

Then, would you let Elon Musk implant a device in your brain? Although Neuralink promises to be a breakthrough medical technology, there's a danger that it could be taken too far. Bloomberg raises concerns about linking our brains to computers.

Elon Musk's Neuralink

Stay connected with the biggest global stories in business and tech. Presented by Karleen Leveille, every weekday on Curio.

In today's episode...

Morale is low among Amazon's workforce. With protest rallies outside the company's Seattle headquarters, Wired explores the factors behind the malaise, including layoffs and broken promises.

Then, what's life like in the age of mass layoffs? As large-scale business firing becomes standard business practice, the Financial Times discusses the unexpected consequences for the future of work.

Big Tech's walk outs & layoffs

Stay connected with the biggest global stories in business and tech. Presented by Karleen Leveille, every weekday on Curio.

In today's episode...

Nvidia has become the first chipmaker to hit a $1tn valuation and join an elite group of U.S.-listed companies, including Apple. The Financial Times reports that the Silicon Valley-based company is leading a surge of enthusiasm across Wall Street by riding the AI wave.

Then, with Nvidia stocks surging, Bloomberg reports that their CEO Jensen Huang has received a rock-star-worthy reception in Taiwan. Discover the company's recent success in the age of AI and what's coming next.

How AI got Nvidia in the $1 trillion Club

Stay connected with the biggest global stories in business and tech. Presented by Karleen Leveille, every weekday on Curio.

In today's episode...

Weight loss startup Noom once touted mindfulness, and now it's jumped on the obesity drug wave to add pharmaceuticals into the equation. Bloomberg reports how the startup is the latest weight loss company aiming to capitalise on the craze. 

Then, WeightWatchers is getting a makeover. With obesity drugs such as Ozempic becoming some of the most profitable pharmaceuticals in the industry, The Wall Street Journal explains why getting into the business of weight loss drugs makes financial sense.

Why are weight loss apps prescribing drugs?

Stay connected with the biggest global stories in business and tech. Presented by Karleen Leveille, every weekday on Curio.

In today's episode...

Law firms with a global reach have significant advantages in our international world. Therefore, Bloomberg explains why creating a transatlantic network makes sense ahead of London-based Allen & Overy and New York firm Shearman & Sterling's $3.4bn merger. 

Then, what's Wim Dejonghe's vision for Allen & Overy's future with Shearman? The Financial Times reports on the "Belgian rainmaker's" long-held ambitions for one of the biggest deals in the industry's history.

A breakdown of the biggest deal in the law industry's history

Stay connected with the biggest global stories in business and tech. Presented by Karleen Leveille, every weekday on Curio.

In today's episode...

A year after Y. Michele Kang purchased Washington Spirit for $35mn, she's making another big splash in women's soccer (football). The Washington Post explores her plans to create a global network to advance the women's game.

Then, Sixth Street Partners will become the first institutional investor to be a majority owner of a professional U.S. sports franchise after buying a women's football club for $125mn. The Financial Times reports on this historic deal.

The business of women's soccer

Stay connected with the biggest global stories in business and tech. Presented by Karleen Leveille, every weekday on Curio.

In today's episode...

Is $9bn enough compensation for thousands impacted by alleged cancer-causing talc? The Wall Street Journal breaks down the history and facts behind what could be one of the biggest product-liability settlements ever. 

Then, could Bayer's new CEO be exactly what they need? Still struggling with the fallout from an ill-fated 2016 acquisition, the Financial Times discovers plans to save the conglomerate as investors push for a breakup. 

How litigation is changing the pharmaceutical industry

Stay up-to-date with the biggest stories in tech and business. Every weekday.

More from Connected

More from Connected